Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Treatment-Resistant Depression: early-phase trial registry
20 of 55 indexed Treatment-Resistant Depression trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #254 of 28,707 conditions by registered trial count.
55 US clinical trials · 20 currently recruiting · #254 of 28,707 conditions by registered trial count
Treatment-Resistant Depression: 55 US clinical trials tracked, 20 recruiting.
Treatment-Resistant Depression is the subject of 55 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 5 of these trials.
Enrollment posture brief
Registry condition treatment-resistant-depression
OPEN 20 | RECR 36% | LATE 7 | EARLY 19 | RANK #254 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acquired Brain Injury (36% recruiting · 11 trials)
Treatment-Resistant Depression lists 20 open slots (36% of 55 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Treatment-Resistant Depression on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Treatment-Resistant Depression is recruiting below its size-band peers.
20 of 55 indexed trials (36.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Treatment-Resistant Depression trials is spread across many organizations.
Washington University School of Medicine accounts for 5 of 55 trials (9.1%). 38 distinct sponsors appear on at least one study for this condition label.
-
Most Treatment-Resistant Depression trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 55 trials that report a genuine target (sentinel values excluded). 37 of those (67.3%) plan for fewer than 100 participants.
-
Treatment-Resistant Depression research is mostly interventional.
51 interventional and 4 observational studies make up this index (92.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
55 total, page 1 of 2
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
LivaNova
NCT03887715
University of Iowa Interventional Psychiatry Service Patient Registry
Mark Niciu
NCT04480918
Biomarker-guided rTMS for Treatment Resistant Depression
Weill Medical College of Cornell University
NCT04041479
Antidepressant Effects of Nitrous Oxide
University of Chicago
NCT05357040
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
atai Therapeutics
NCT06524830
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
Laureate Institute for Brain Research
NCT07166289
Psilocybin rTMS for Treatment Resistant Depression
University of Texas at Austin
NCT06132178
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Abbott Medical Devices
NCT06423430
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing
Baylor College of Medicine
NCT05418894
Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI
University of California, San Diego
NCT05377177
Maintenance rTMS for Depression (Maitr-De)
University of California, San Diego
NCT06938841
Mindfulness Engaged Neurostimulation for Depression
University of California, San Diego
NCT06399406
Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder
Stanford University
NCT05849402
Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy
Washington University School of Medicine
NCT05905705
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
University of North Carolina, Chapel Hill
NCT06303739
DBS for Depression
Northwell Health
NCT06096207
PCS in Severe Treatment Resistant Depression
University of Minnesota
NCT04124341
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
University of Utah
NCT06329414
Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression
Nader Pouratian
NCT03952962
DBS for TRD With the Medtronic Percept PC
Helen Mayberg, MD
NCT05773755
Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression
University of Texas Southwestern Medical Center
NCT06002204
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
COMPASS Pathways
NCT05711940
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
COMPASS Pathways
NCT05624268
Rapid Acting Transcranial Magnetic Stimulation
Stanford University
NCT04739969
Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation
Stanford University
NCT04243798
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
Massachusetts General Hospital
NCT05774665
Neural and Antidepressant Effects of Propofol
University of Utah
NCT03684447
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Washington University School of Medicine
NCT05838560
Compressed Intermittent Theta Burst Stimulation
University of Pennsylvania
NCT04684706
Psilocybin for Treatment-Resistant Depression
University of Colorado, Denver
NCT06230757
CET- REM (Correlating ECT Response to EEG Markers)
Washington University School of Medicine
NCT04451135
Exercise to Augment TMS in Those With Treatment Resistant Depression
Butler Hospital
NCT05913401
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Sheppard Pratt Health System
NCT04433858
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
Mayo Clinic
NCT03573349
Open Label - Personalized Therapeutic Neuromodulation for Anhedonic Depression
Stanford University
NCT06052137
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
The University of Texas Health Science Center, Houston
NCT02046330
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
Washington University School of Medicine
NCT04680910
Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD)
Mayo Clinic
NCT06236711
Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S
Emory University
NCT01984710
DBS for TRD With the Medtronic Summit RC+S
Helen Mayberg, MD
NCT04106466
Epidural Cortical Stimulation for Depression
Medical University of South Carolina
NCT00565617
A Study in Relapse Prevention of Treatment-Resistant Depression
Eli Lilly and Company
NCT00958568
Open-Label Safety Study of AXS-05 in Subjects With Depression
Axsome Therapeutics
NCT04039022
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
Washington University School of Medicine
NCT02960763
Implementation Trial of Evidence Based Practices for Mood Disorders
University of Arkansas
NCT02150577
A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
Denovo Biopharma
NCT05113771
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)
Massachusetts General Hospital
NCT01920555
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Navitor Pharmaceuticals
NCT03606395
Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression
VA Office of Research and Development
NCT02360280
Home-administered tDCS for Treatment of Depression
Soterix Medical
NCT04781127
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 13 |
| Phase 3 | 6 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Treatment-Resistant Depression records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Treatment-Resistant Depression trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Treatment-Resistant Depression page
55 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 20 Treatment-Resistant Depression trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Treatment-Resistant Depression trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Treatment-Resistant Depression condition card totals 55 registered trials; most-linked intervention Psilocybin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.